-First-and-Only-Ready-to-Dilute-Multi-Dose-Vial-of-Thiotepa-Approved

Originally published by our sister publication Clinical Oncology NewsBy Clinical Oncology News StaffShorla Oncology, a U.S.-Ireland specialty pharmaceutical company, announced that the FDA has granted approval for the 100 mg/10 mL multi-dose vial of Tepylute, a ready-to-dilute formulation of thiotepa to treat breast and ovarian cancers, that eliminates the need for reconstitution and may reduce preparation time and errors, thus offering more scheduling flexibility for patients.“We are plea